Dr. Papadimitrakopoulou Provides an Update on Pembrolizumab for Lung Cancer

Vassiliki Papadimitrakopoulou, MD
Published: Friday, Nov 07, 2014

Vassiliki Papadimitrakopoulou, MD, Professor, Department of Thoracic/Head and Neck Medical Oncology, University of Texas MD Anderson Cancer Center, provides an update on research into pembrolizumab (Keytruda) for the treatment of lung cancer.

Pembrolizumab is currently being studied in patients whose tumors express PD-L1. This is a smart enrichment strategy for treating patients, Papadimitrakopoulou says, and the activity seen so far could be because of this selection. However, all evidence so far points to good activity with this agent in all settings of non-small cell lung cancer.

SELECTED
LANGUAGE
Vassiliki Papadimitrakopoulou, MD, Professor, Department of Thoracic/Head and Neck Medical Oncology, University of Texas MD Anderson Cancer Center, provides an update on research into pembrolizumab (Keytruda) for the treatment of lung cancer.

Pembrolizumab is currently being studied in patients whose tumors express PD-L1. This is a smart enrichment strategy for treating patients, Papadimitrakopoulou says, and the activity seen so far could be because of this selection. However, all evidence so far points to good activity with this agent in all settings of non-small cell lung cancer.


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Advances in™ Therapies for Patients With ALK-Positive Lung Cancers: More Options…More Decisions…Better OutcomesAug 30, 20191.5
Oncology Briefings™: Treating Advanced NSCLC Without Actionable MutationsAug 30, 20191.0
Publication Bottom Border
Border Publication
x